A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 274 participants.

Also called NCT06777238

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 274 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06777238
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06777238. Randomized; triple masking; primary purpose treatment. Start 2025-02-24 (actual); primary completion 2026-07-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Subjects With Type 2 Diabetes Mellitus and Poor Blood Glucose Control by Diet and Exercise
Acronym
Optimum 1
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Drug)
GZR18
Intervention (Drug)
Placebo
Lead sponsor
Gan & Lee Pharmaceuticals. (class: industry)

Record details

Record id
cardio:ct-nct06777238
Content hash
e358ec6514504e05673757ad17dc6e6478f90a8e01bec9eed53e347a0504af25